Latent TB and Active TB: Understading the Difference

Introduction

Latent tuberculosis (TB) infection is characterized by Mycobacterium tuberculosis in the body without symptoms of illness or contagion. In contrast, active TB disease occurs when the bacteria become active, causing symptoms and posing a risk of transmission. Early detection and treatment of latent TB are crucial to prevent its progression to active disease.

What Is Tuberculosis?

Tuberculosis (TB) is caused by Mycobacterium tuberculosis. It is a communicable bacterial infection. While the lungs are the main organ affected, the kidneys, spine, and brain may also be affected. TB spreads through the air when an infected person coughs or sneezes, with symptoms including coughing, chest pain, weight loss, fever, and fatigue. It can be latent, where the immune system keeps the bacteria in check, or active, posing a serious health risk. Treatment involves a course of antibiotics over several months. With proper medical care, TB is curable, but untreated cases can be fatal and contribute to public health concerns.

What Is Latent TB and Active TB?

Tuberculosis (TB) manifests in two main forms: latent TB infection (LTBI) and active TB disease.

• Latent TB Infection (LTBI): Latent TB occurs when a person has been infected with the TB bacteria but does not display disease symptoms and is not contagious. In latent TB, the bacteria remain dormant in the body, usually residing in the lungs, without causing any symptoms or spreading to other people. The immune system can keep the bacteria in check, preventing them from multiplying and causing illness. However, if the immune system deteriorates and bacteria become active, latent tuberculosis can develop into active tuberculosis disease.

• Active TB Disease: When the tuberculosis bacteria become active and increase, resulting in symptoms and spreadability, active tuberculosis disease arises. This typically happens when the immune system weakens, often due to factors such as HIV infection, malnutrition, or other illnesses. Active TB commonly affects the lungs (pulmonary TB) but can also affect other body parts (extrapulmonary TB), such as the kidneys, spine, or brain. Symptoms of active TB include persistent cough, chest pain, weight loss, fever, night sweats, and fatigue. Without proper treatment, active TB can be severe, potentially leading to complications and death.

Various tests, including TB skin tests, blood tests, and imaging studies, diagnose both latent and active TB. Treatment for latent TB typically involves a course of antibiotics to prevent the bacteria from becoming active. Active TB requires a more extended and intensive treatment regimen to eliminate the bacteria and prevent transmission to others.

How Is Latent TB Diagnosed?

Diagnosing latent tuberculosis (TB) infection (LTBI) is crucial for preventing the progression to active TB disease and for implementing appropriate treatment to reduce the risk of transmission. Several methods are used to diagnose LTBI, each with its advantages and limitations:

• Tuberculin Skin Test (TST):

  • TST, often called the Mantoux tuberculin skin test, entails subcutaneous injection of a tiny quantity of pure protein derivative (PPD) solution, usually on the forearm.

  • After 48 to 72 hours, a healthcare provider examines the injection site for a raised, firm, red bump (induration) and measures its size.

  • Interpretation of the test result considers factors such as the individual's age, medical history, and other risk factors.

  • False-positive results may occur due to prior Bacillus Calmette-Guérin (BCG) vaccination or exposure to non-tuberculous mycobacteria. False-negative results can occur in immunocompromised individuals.

• Interferon-Gamma Release Assays (IGRAs):

  • IGRAs measure interferon-gamma release by T-cells in response to specific TB antigens.

  • Blood samples are collected and incubated with TB-specific antigens, and then the amount of interferon-gamma released is measured.

  • ESAT-6 and CFP-10 are common antigens used in IGRAs, but they are not found in BCG or most non-tuberculous mycobacteria.

  • IGRAs are not affected by BCG vaccination but can be affected by immunosuppression.

• Chest X-ray and Physical Examination:

  • While not specific for LTBI, chest X-rays may reveal signs suggestive of prior TB infection, such as calcifications or scarring in the lungs.

  • During a physical examination, swollen lymph nodes may be seen, particularly in the neck.

• Risk Assessment:

  • Healthcare providers assess an individual's risk factors for TB infection, including recent exposure to active TB cases, living in or traveling to high-prevalence areas, and immunosuppression.

  • Risk assessment is often used with other diagnostic tests to guide LTBI diagnosis and treatment decisions.

The choice of a diagnostic test may depend on factors such as availability, cost, and patient preference. In some cases, multiple tests may be used to increase diagnostic accuracy.

It's important to note that LTBI diagnosis does not require symptoms of TB disease. Early detection and treatment of LTBI can prevent the progression of active TB disease, reducing morbidity, mortality, and transmission in the community. Therefore, individuals at risk for LTBI, including those with recent TB exposure or immunosuppression, should undergo regular screening and evaluation by healthcare providers.

How Can Latent TB Be Treated?

An individual who has been exposed to the TB bacteria but does not show any symptoms or feel ill is considered to have a latent tuberculosis (TB) infection. It is essential to diagnose and treat latent TB to prevent it from progressing into active TB disease, which is contagious and can cause severe illness. Here's how latent TB can be treated:

• Medication:

  • The most common treatment for latent TB is a course of antibiotics, usually Isoniazid (INH) or Rifampin (RIF). Other options include a combination of INH and Rifapentine (RPT).

  • Depending on the drug plan selected, the course of treatment can last anywhere from three to nine months.

  • Depending on factors like the patient's age, the type of drug used, the length of the treatment, risk factors, drug resistance patterns, and tolerability.

  • Directly Observed Therapy (DOT) may be recommended, where a healthcare provider ensures that the individual takes their medication as prescribed to improve adherence and treatment completion rates.

• Monitoring:

  • Regular monitoring is essential during latent TB treatment to assess treatment response and monitor for adverse effects.

  • Healthcare providers may conduct periodic clinical evaluations, including physical exams and symptom assessments, to monitor for signs of active TB disease or medication side effects.

  • Blood tests, such as interferon-gamma release assays (IGRAs) or tuberculin skin tests (TSTs), may monitor treatment response by evaluating the immune system's reaction to TB antigens.

• Education and Support:

  • Healthcare providers should educate individuals undergoing latent TB treatment about the importance of medication adherence, potential side effects, and the need to complete the full course of treatment.

  • Providing support and addressing individuals' concerns or questions about their treatment can enhance adherence and success.

  • Counseling on lifestyle factors supporting treatment, such as maintaining a healthy diet, regular exercise, and avoiding alcohol or drug use, may also be beneficial.

• Follow-Up:

  • After completing latent TB treatment, individuals may undergo follow-up evaluations to ensure the infection has been successfully treated and monitor for any signs of TB recurrence.

  • Follow-up may involve repeat testing, such as TB skin tests or blood tests, to confirm treatment success and rule out active TB disease.

  • Healthcare providers may also offer ongoing support and monitoring to individuals at continued TB infection or reactivation risk.

Conclusion

Understanding the distinctions between latent TB and active TB is essential for effective TB control strategies. Latent TB requires identification and treatment to prevent progression to active disease and reduce transmission risk. Active TB demands prompt diagnosis and treatment to mitigate its impact on individuals and communities. Both forms of TB necessitate concerted efforts in public health to achieve TB elimination goals.